Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Genmab A/S (GNMSF : OTC)
 
 • Company Description   
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.

Number of Employees: 2,682

 
 • Price / Volume Information   
Yesterday's Closing Price: $198.51 Daily Weekly Monthly
20 Day Moving Average: 38 shares
Shares Outstanding: 66.07 (millions)
Market Capitalization: $13,116.28 (millions)
Beta: 0.91
52 Week High: $292.80
52 Week Low: $170.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.99% -13.92%
12 Week 10.90% -6.96%
Year To Date -4.28% -10.34%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
CARL JACOBSENS VEJ 30
-
VALBY,G7 2500
DNK
ph: 45-7020-2728
fax: 45-7020-2729
ir@genmab.com http://www.genmab.com
 
 • General Corporate Information   
Officers
Jan G. van de Winkel - President and Chief Executive Officer
Anthony Mancini - Executive Vice President and Chief Operating Offic
Anthony Pagano - Executive Vice President and Chief Financial Offic
Judith Klimovsky - Executive Vice President
Birgitte Stephensen - Executive Vice President

Peer Information
Genmab A/S (CORR.)
Genmab A/S (RSPI)
Genmab A/S (CGXP)
Genmab A/S (BGEN)
Genmab A/S (GTBP)
Genmab A/S (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: K3967W102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 66.07
Most Recent Split Date: (:1)
Beta: 0.91
Market Capitalization: $13,116.28 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 13.41
PEG Ratio: -
Price Ratios
Price/Book: 2.48
Price/Cash Flow: 13.07
Price / Sales: 4.06
EPS Growth
vs. Year Ago Period: 3.74%
vs. Previous Quarter: -46.49%
Sales Growth
vs. Year Ago Period: 18.53%
vs. Previous Quarter: -22.39%
ROE
06/30/25 - -
03/31/25 - 19.23
12/31/24 - 19.75
ROA
06/30/25 - -
03/31/25 - 15.44
12/31/24 - 16.23
Current Ratio
06/30/25 - -
03/31/25 - 5.34
12/31/24 - 5.25
Quick Ratio
06/30/25 - -
03/31/25 - 5.32
12/31/24 - 5.24
Operating Margin
06/30/25 - -
03/31/25 - 29.44
12/31/24 - 30.43
Net Margin
06/30/25 - -
03/31/25 - 35.11
12/31/24 - 36.30
Pre-Tax Margin
06/30/25 - -
03/31/25 - 40.96
12/31/24 - 42.57
Book Value
06/30/25 - -
03/31/25 - 80.15
12/31/24 - 80.53
Inventory Turnover
06/30/25 - -
03/31/25 - 17.23
12/31/24 - 14.25
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©